Belgian drugmaker Ablynx reported results from a Phase I study of its antithrombotic ALX-0081.

The results of the double-blind, placebo-controlled study in 40 healthy male volunteers demonstrated ALX-0081 was safe and well tolerated at all doses tested with no dose limiting toxicities or serious adverse events.

The compound’s pharmacological activity started at the 2-mg dose and reached a maximum duration of 12 hours at a dose of 12 mg. 

Edwin Moses, Ablynx’s CEO and chair, said the company hopes to start the next study with the compound with acute coronary syndrome and thrombocytopenic purpura patients in 2008.